- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00003156
Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus
Evaluation of Topotecan in the Treatment of Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of topotecan in treating patients with recurrent or refractory cancer of the uterus.
Study Overview
Detailed Description
OBJECTIVES: I. Estimate the antitumor activity of topotecan in patients with recurrent or refractory carcinosarcoma of the uterus who have failed standard therapy. II. Determine the nature and degree of toxic effects of topotecan in these patients.
OUTLINE: Patients receive topotecan IV over 30 minutes daily for 5 days. Treatment repeats every 3 weeks for a minimum of 1 course in the absence of disease progression or unacceptable toxicity. Patients with complete response, partial response, or stable disease continue treatment for at least three courses. Patients are followed every 4 months for 2 years, every 6 months for 3 years, and then periodically thereafter until death.
PROJECTED ACCRUAL: Approximately 25-40 patients will be accrued for this study within 2 years.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N2
- Tom Baker Cancer Center - Calgary
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama Comprehensive Cancer Center
-
-
California
-
Los Angeles, California, United States, 90095-1781
- Jonsson Comprehensive Cancer Center, UCLA
-
Los Gatos, California, United States, 95032
- Community Hospital of Los Gatos
-
Orange, California, United States, 92868
- Chao Family Comprehensive Cancer Center
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20307-5000
- Walter Reed Army Medical Center
-
-
Florida
-
Tampa, Florida, United States, 33612
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush-Presbyterian-St. Luke's Medical Center
-
Chicago, Illinois, United States, 60637
- University of Chicago Cancer Research Center
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202-5265
- Indiana University Cancer Center
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Hospitals and Clinics
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- Radiation Oncology Branch
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Tufts University School of Medicine
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Barbara Ann Karmanos Cancer Institute
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota Cancer Center
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216-4505
- University of Mississippi Medical Center
-
-
Missouri
-
Columbia, Missouri, United States, 65203
- Ellis Fischel Cancer Center - Columbia
-
Kansas City, Missouri, United States, 64131
- CCOP - Kansas City
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
New York
-
Albany, New York, United States, 12208
- Cancer Center of Albany Medical Center
-
Brooklyn, New York, United States, 11203
- State University of New York Health Science Center at Brooklyn
-
Manhasset, New York, United States, 11030
- North Shore University Hospital
-
Stony Brook, New York, United States, 11790-7775
- State University of New York Health Sciences Center - Stony Brook
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599-7295
- Lineberger Comprehensive Cancer Center, UNC
-
Durham, North Carolina, United States, 27710
- Duke Comprehensive Cancer Center
-
Winston-Salem, North Carolina, United States, 27157-1082
- Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Barrett Cancer Center, The University Hospital
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Taussig Cancer Center
-
Cleveland, Ohio, United States, 44106-5065
- Ireland Cancer Center
-
Columbus, Ohio, United States, 43210
- Arthur G. James Cancer Hospital - Ohio State University
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73190
- University of Oklahoma College of Medicine
-
Tulsa, Oklahoma, United States, 74136
- CCOP - Sooner State
-
-
Pennsylvania
-
Abington, Pennsylvania, United States, 19001
- Abington Memorial Hospital
-
Hershey, Pennsylvania, United States, 17033
- Milton S. Hershey Medical Center
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania Cancer Center
-
Wynnewood, Pennsylvania, United States, 19096
- CCOP - MainLine Health
-
-
South Carolina
-
Spartanburg, South Carolina, United States, 29303
- CCOP - Upstate Carolina
-
-
Tennessee
-
Memphis, Tennessee, United States, 38117
- CCOP - Baptist Cancer Institute
-
Nashville, Tennessee, United States, 37203
- Brookview Research, Inc.
-
-
Texas
-
Dallas, Texas, United States, 75235-9154
- Simmons Cancer Center - Dallas
-
Temple, Texas, United States, 76508
- CCOP - Scott and White Hospital
-
-
Vermont
-
Burlington, Vermont, United States, 05401
- Fletcher Allen Health Care
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- Cancer Center, University of Virginia HSC
-
-
Washington
-
Seattle, Washington, United States, 98195-6043
- University of Washington Medical Center
-
Tacoma, Washington, United States, 98405
- Tacoma General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS: Histologically proven recurrent or refractory carcinosarcoma (mixed mesodermal tumors) of the uterus Measurable disease
PATIENT CHARACTERISTICS: Age: Not specified Performance Status: GOG 0-2 Life Expectancy: Not specified Hematopoietic: Platelet count at least 100,000/mm3 Absolute granulocyte count at least 1,500/mm3 Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT no greater than 3 times ULN Alkaline phosphatase no greater than 3 times ULN Renal: Creatinine no greater than 1.5 mg/dL Creatinine clearance greater than 20 mL/min Other: No invasive malignancies within the past 5 years except nonmelanomatous skin cancer No significant infection
PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 weeks since prior biologic therapy Chemotherapy: At least 3 weeks since prior chemotherapy and recovered No prior topotecan or camptothecin therapy No more than 1 prior chemotherapy regimen (either single or combination chemotherapy) Endocrine therapy: At least 3 weeks since prior endocrine therapy Radiotherapy: At least 3 weeks since prior radiotherapy and recovered Surgery: Prior surgery allowed and recovered
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDR0000065948
- GOG-130D
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcoma
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedUterine Corpus Leiomyosarcoma | Stage IIA Uterine Sarcoma | Stage IIB Uterine Sarcoma | Stage IIIA Uterine Sarcoma | Stage IIIB Uterine Sarcoma | Stage IIIC Uterine Sarcoma | Stage IVA Uterine Sarcoma | Stage IVB Uterine Sarcoma | Stage IA Uterine Sarcoma | Stage IB Uterine Sarcoma | Stage IC Uterine SarcomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedBone Sarcoma | Retroperitoneal Sarcoma | Adult Soft Tissue SarcomaUnited States
-
Mohammed M MilhemGenentech, Inc.CompletedSarcoma | Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)CompletedRhabdomyosarcoma | Synovial Sarcoma | Ewing's Sarcoma | MPNST | High-risk SarcomaUnited States
-
Epizyme, Inc.RecruitingAdvanced Soft-tissue Sarcoma | Advanced Epithelioid SarcomaUnited States, Taiwan, Canada, United Kingdom
-
Brown UniversityActuate Therapeutics Inc.WithdrawnSoft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma of Bone | Leiomyosarcoma | High Grade Sarcoma | Liposarcoma | Rhabdomyosarcoma | Angiosarcoma | Bone Sarcoma | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Myxofibrosarcoma | Spindle Cell SarcomaUnited States
-
David DickensWithdrawnSoft Tissue Sarcoma | Bone Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft-tissue Sarcoma | Metastatic Bone Sarcoma | Unresectable Bone SarcomaUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Stage IIA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma
Clinical Trials on topotecan hydrochloride
-
CelgeneCompletedSmall Cell Lung CancerUnited States, United Kingdom, Australia, France, Canada, Netherlands, Poland, Spain, Switzerland, Italy, Denmark, Hungary, Germany, Bulgaria, Czechia, Austria, Belgium
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedMyelodysplastic Syndromes | LeukemiaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedLung CancerUnited States
-
National Cancer Institute (NCI)CompletedSarcomaUnited States, Canada, Puerto Rico, Australia, Netherlands, New Zealand, Switzerland
-
NYU Langone HealthOSI PharmaceuticalsTerminated
-
National Cancer Institute (NCI)CompletedRecurrent Small Cell Lung CarcinomaUnited States, Singapore
-
NCIC Clinical Trials GroupCompletedBrain and Central Nervous System TumorsCanada
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)TerminatedOvarian Cancer | Primary Peritoneal Cavity CancerUnited States, Canada